A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong

Size: px
Start display at page:

Download "A Dynamic Model of Care for Late Onset Cognitive Impairment. Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong"

Transcription

1 A Dynamic Model of Care for Late Onset Cognitive Impairment Linda CW Lam Department of Psychiatry The Chinese University of Hong Kong

2 Outline The pathogenesis of Late life cognitive impairment A framework of care

3 The golden age.. Age (Cambridge dictionary) The period of time someone has been alive The Life Cycle Course of developmental changes from inception as fertilized zygote to a mature reproductive state, followed by subsequent decline

4 At 85 years old, you may experience Reduced motility Reduced interests Forgetfulness Repetitiveness Mini-mental state exam 24/30 Delayed recall 2/10 1 minute animal fluency test 10 examplars

5 Brain Imaging Serial MRI brain scans, taken six months apart, show progression from mild cognitive impairment to Alzheimer's disease, with significant atrophy (blue) and ventricle enlargement (orange/red). (University of California, San Diego, UCSD)

6 Brain Imaging Klunk, W.E., et al., Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Annals of Neurology, 2004;55:306-19

7 Alzheimer s disease

8 Alzheimer Disease Anatomical diagnosis of Auguste Deter Cerebral atrophy Arteriosclerosis of small blood vessels Presentation by Alzheimer at conference in Tubingen (1906) Fibrils with characteristics thickness (tangles) Small miliary foci (plaques)

9 Amyloid protein leads to AD. The Amyloid Cascade Hypothesis Amyloid Precursor Protein Aß plaques Aß Aß oligomer Aß Fibrils P-Tau Excitotoxicity Inflammation Oxidation Mitochondrial dysfunction Neurofibrillary tangles Synapse failure, Cell Death Cummings, Alz Dement, 2011

10 How does Alzheimer s disease develop?

11 A life course approach AGE Dementia Alzheimer disease

12 At conception Early onset AD Amyloid precursor gene (21) Presenilin 1 gene (14) Presenilin 2 gene (1) Late onset AD Apolipoprotein E gene (19) Gene dose effects Advance age of onset >200 genes identified Inflammatory pathway, energy metabolism, neuronal repair, estrogen, immune response Tanzi et al., Nature, 1987;329(6135): ; Lewy-Lahad et al., Science 1995;269: ; Sherrington et al., Nature, 1995;375 (6534): ; Corder et al., Science 1993;261(5123):

13 Early Life Environmental Enrichment Transgenic and wild type mice were either housed under standard conditions or in an enriched environment. Standard housed Transgenic mice Diminished hippocampal cell proliferation Reduced number of mature newborn neurons. Environmental enrichment reversed this genotype effect. Cognitive and physical stimulation Increasing the number of newborn mature hippocampal neurons in transgenic mice. Herring A, Exp Neurol. 2009;216:

14 A life course approach Dementia Alzheimer disease

15 Education High education is a protective factor for the development of dementia. Enhanced cognitive reserve? Higher education delay the onset of decline. Modulate clinical manifestations of disease burden? Valenzuela & Sachdev, Psychol Med, 2006; Wilson et al., Arch Gen Psy, 2007; Rosell F et al., Clin Neurol Neurosurg; Hall CD et al., Neurology, 2007;

16 Education, the brain and Dementia Population-based cohort studies (Epidemiological Clinicopathological Studies in Europe; EClipSE) 3 population-based studies that included 827 post-mortem brain donation and Longer years in education at early life were associated Decreased dementia risk and greater brain weight No relationship to neurodegeneration. EclipSE Collaborative Members, Brayne C, et al. Brain 2010; 133:2210-6

17 A life course approach Dementia Alzheimer disease

18 Early Linguistic Ability - The Nun Study A longitudinal study on aging and disability using antemortem and postmortem data collected from 678 older School Sisters of Notre Dame since The causes and prevention of Alzheimer's disease, The mental and physical disability associated with old age. Healthy Aging versus dementia AD pathology Stroke Early linguistic ability Education Snowdon. et al., JAMA. 1997;277: ; Tyas et al., Age Ageing. 2007;36:

19 Occupation In a religious order study of 517 Bavarian school sisters, risk of dementia was associated with Low education (OR 4.5, 95%CI ) Not having vocational training (OR 9.1, 95% CI ) Never been appointed to a leading position (OR 3.7, 95% CI ) Bickel & Kurz, Dement Geriatr Cogn Disord, 2009;27:

20 A life course approach Dementia Alzheimer disease

21 Mid Life Body Mass Index and AD In a meta analysis Low BMI, increased risk of AD (OR 1.96, 95% CI: ) Overweight BMI, increased risk of AD (OR 1.35, ), VaD (OR 1.26, ) U-shape curve Anstev et al, Obse Rev 2011;12:e426-37

22 Atherosclerosis and dementia Rotterdam study A population based cohort of over 6600 subjects followed up with a mean of 9 years. Atherosclerosis, especially carotid plaques, are associated with an increased risk for dementia. Van Oijen et al, Ann Neurology, 2007;

23 Cognitive activities & cognitive function Cognitive activities (reading, playing board games, musical instruments, dancing) dementia risk Late life cognitive activities delayed onset of accelerated memory decline more rapid decline after onset. Stimulating leisure activities dementia risk and AD over a 4 year period in the Three-City Study in France. Midlife cognitive activity, but not physical activity, modulated risk of dementia in monzygotic twins pairs. Verghese et al., NEJM, 2003; Hall et al., Neurology, 2009; Akbaraly et al., Neurology, 2009; Carlson et al., 2008.

24 Physical activities & cognitive function Leisure time physical activity lower mortality in a US national cohort. A 24-week home based physical activity intervention provided a modest improvement in cognition over an 18-month followup period. 6 months aerobic exercise associated sex-specific effects on cognition, glucose metabolism and hypothalamic- pituitary adrenal axis. 12 months resistance training improved executive function (Stroop test) over balance and toning. Lautenschlager et al., JAMA, 2008; Gillum & Obisesan, 2010, Ann Epidemiol, 2010; Baker et al., Arch Neurol., 2010; Liu-Ambrose et al., Arch Intern Med., 2010.

25 A life course approach Dementia Alzheimer disease

26 Amyloid ß deposition in clinical normal elders Aβ deposition in cognitively normal elders is Age-related Associated with cortical thinning Hippocampal atrophy, Aβ deposition in temporal neocortex are associated with episodic memory loss in pre-dementia stage Becker et al, Ann Neurol, 2011;69: Chetelat et al., Brain 2011;134:

27 Vascular lesions in AD brains Vascular lesions Major infarcts, lacunes, microbleeds, white matter degeneration Mixed with AD pathology Synergistic effects on clinical symptoms & disease course Jellinger. J Alz Dis., 2008;14:

28 What determines the development of AD?

29 Sperling et al, Alz Dementia; 2011

30 Hypothetical Model of AD Pathophysiological Cascade Jack CR Jr. et al, Lancet Neurol, 2010

31 A framework of care From prevention to treatment A personalized approach

32 Primary Prevention From Early to Adult Life AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Perinatal Care Health Care in early life School Education Social and Leisure enrichment Occupation Safety Substance misuse

33 Primary Prevention From Mid Life AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing cardiovascular and brain health Vascular risks Depression Physical exercise Cognitive activities Social network and support Diet

34 At Late Life Preclinical & Prodromal Phase AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing cardiovascular and brain health Vascular risks Depression Physical exercise Cognitive activities Social network and support Diet Structured approach to intervention?

35 A personalized approach to dementia care Risk assessment Genetic Physical Health Cognitive reserve Early biomarker changes Intervention Stage dependent Modality Constitutional factors (Pharmacogenetics)

36 Alzheimer s disease Mild AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing physical Health Caregiver involvement Cognitive and functional maintenance Acetylcholine esterase inhibitors Functional training for IADL

37 Alzheimer s disease Moderate AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing physical Health Caregiver involvement Cognitive and functional maintenance Acetylcholine esterase inhibitors/ NMDA receptor antagonist Management of neuropsychiatric symptoms Functional training for BADL Consideration for day training

38 Alzheimer s disease Severe AGE Early factors Genes Intelligence Education Occupation Personality Midlife vascular health Exercise, Diet, Lifestyles Brain Lesions Optimizing physical Health Caregiver involvement Acetylcholine esterase inhibitors/ NMDA receptor antagonist Management of neuropsychiatric symptoms Support for BADL and physiological function Consideration for long term care

39 Dynamic model A patient Journey Preclinical Prodromal Clinical Enhancing Cognitive Reserve Attention to brain health Optimizing cognition Reduce psychiatric and physical morbidity Community Health care services Outpatients Hospitals Long term care

40 To tackle late life cognitive impairment.. Never too early Avoids being too late

41 Thank you

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT

DISCLOSURES. Objectives. THE EPIDEMIC of 21 st Century. Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia NONE TO REPORT Clinical Assessment of Cognition: New & Emerging Tools for Diagnosing Dementia DISCLOSURES NONE TO REPORT Freddi Segal Gidan, PA, PhD USC Keck School of Medicine Rancho/USC California Alzheimers Disease

More information

Stephen Salloway, M.D., M.S. Disclosure of Interest

Stephen Salloway, M.D., M.S. Disclosure of Interest Challenges in the Early Diagnosis of Alzheimer s Disease Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University 2 nd Annual Early Alzheimer s Educational

More information

TGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci

TGF-ß1 pathway as a new pharmacological target for neuroprotection in AD. Filippo Caraci Department of Clinical and Molecular Biomedicine Section of Pharmacology and Biochemistry Department of Educational Sciences University of Catania TGF-ß1 pathway as a new pharmacological target for neuroprotection

More information

The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults

The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults The Primary Care Guide To Understanding The Role Of Diabetes As A Risk Factor For Cognitive Loss Or Dementia In Adults. Introduction Glucose intolerance is common in older individuals and this metabolic

More information

The role of the vascular system in dementia

The role of the vascular system in dementia The role of the vascular system in dementia James AR Nicoll Professor of Neuropathology, University of Southampton Consultant Neuropathologist, Southampton General Hospital What does the vascular system

More information

Understanding Symptoms, Causes, and Risks for Alzheimer s Disease

Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Understanding Symptoms, Causes, and Risks for Alzheimer s Disease Gene E. Alexander, Ph.D., Professor of Psychology, Neuroscience, and Physiological Sciences; Director, Brain Imaging, Behavior & Aging

More information

Mild Cognitive Impairment (MCI)

Mild Cognitive Impairment (MCI) October 19, 2018 Mild Cognitive Impairment (MCI) Yonas E. Geda, MD, MSc Professor of Neurology and Psychiatry Consultant, Departments of Psychiatry & Psychology, and Neurology Mayo Clinic College of Medicine

More information

Alzheimer s Disease Update: From Treatment to Prevention

Alzheimer s Disease Update: From Treatment to Prevention Alzheimer s Disease Update: From Treatment to Prevention Jeffrey M. Burns, MD Edward H. Hashinger Professor of Medicine Co-Director, KU Alzheimer s Disease Center Director, Clinical and Translational Science

More information

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research

8/14/2018. The Evolving Concept of Alzheimer s Disease. Epochs of AD Research. Diagnostic schemes have evolved with the research The Evolving Concept of Alzheimer s Disease David S. Geldmacher, MD, FACP Warren Family Endowed Chair in Neurology Department of Neurology UAB School of Medicine Epochs of AD Research Epoch Years Key Event

More information

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada

Dementia Update. October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Dementia Update October 1, 2013 Dylan Wint, M.D. Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada Outline New concepts in Alzheimer disease Biomarkers and in vivo diagnosis Future trends

More information

Brain Health and Risk Factors for Dementia

Brain Health and Risk Factors for Dementia Welcome To Brain Health and Risk Factors for Dementia Presented by Kamal Masaki, MD Professor and Chair Department of Geriatric Medicine John A. Burns School of Medicine, UH Manoa April 4, 2018 10:00 11:00

More information

The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging

The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging The Epidemiology of Stroke and Vascular Risk Factors in Cognitive Aging REBECCA F. GOTTESMAN, MD PHD ASSOCIATE PROFESSOR OF NEUROLOGY AND EPIDEMIOLOGY JOHNS HOPKINS UNIVERSITY OCTOBER 20, 2014 Outline

More information

Biomarkers for Alzheimer s disease

Biomarkers for Alzheimer s disease Biomarkers for Alzheimer s Disease Henrik Zetterberg, MD, PhD Professor of Neurochemistry The Sahlgrenska Academy, University of Gothenburg 1 Alzheimer s disease 2 Neuropathological criteria for Alzheimer

More information

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient

WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient DEMENTIA WHAT IS DEMENTIA? An acquired syndrome of decline in memory and other cognitive functions sufficient to affect daily life in an alert patient Progressive and disabling Not an inherent aspect of

More information

Imaging of Alzheimer s Disease: State of the Art

Imaging of Alzheimer s Disease: State of the Art July 2015 Imaging of Alzheimer s Disease: State of the Art Neir Eshel, Harvard Medical School Year IV Outline Our patient Definition of dementia Alzheimer s disease Epidemiology Diagnosis Stages of progression

More information

Cognitive ageing and dementia: The Whitehall II Study

Cognitive ageing and dementia: The Whitehall II Study Cognitive ageing and dementia: The Whitehall II Study Archana SINGH-MANOUX NIH: R01AG013196; R01AG034454; R01AG056477 MRC: K013351, MR/R024227 BHF: RG/13/2/30098 H2020: #643576 #633666 Outline Lifecourse

More information

METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF LEVEL OUTPATIENT CLINIC IN ITALY

METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF LEVEL OUTPATIENT CLINIC IN ITALY METABOLIC SYNDROME, NEUROINFLAMMATION AND COGNITIVE IMPAIRMENT: STATE OF THE ART AND DATA FROM A SECOND LEVEL OUTPATIENT CLINIC IN ITALY Valeria Calsolaro Post graduating school on Geriatric medicine University

More information

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky

Type 2 Diabetes and Brain Disease in Older Adults. Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Type 2 Diabetes and Brain Disease in Older Adults Erin L. Abner, PhD, MPH Asst. Professor University Of Kentucky Disclosures to Participants Requirements for Successful Completion: For successful completion,

More information

Brain imaging for the diagnosis of people with suspected dementia

Brain imaging for the diagnosis of people with suspected dementia Why do we undertake brain imaging in dementia? Brain imaging for the diagnosis of people with suspected dementia Not just because guidelines tell us to! Exclude other causes for dementia Help confirm diagnosis

More information

Depression: An Important Risk Factor for Cognitive Decline

Depression: An Important Risk Factor for Cognitive Decline Depression: An Important Risk Factor for Cognitive Decline No conflicts of interest Sarah K. Tighe, M.D. Assistant Professor University of Iowa Carver College of Medicine Department of Psychiatry Institute

More information

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013

USE OF BIOMARKERS TO DISTINGUISH SUBTYPES OF DEMENTIA. SGEC Webinar Handouts 1/18/2013 Please visit our website for more information http://sgec.stanford.edu/ SGEC Webinar Handouts 1/18/2013 2013 WEBINAR SERIES STATE OF THE SCIENCE: DEMENTIA EVALUATION AND MANAGEMENT AMONG DIVERSE OLDER

More information

Diagnosis and Treatment of Alzhiemer s Disease

Diagnosis and Treatment of Alzhiemer s Disease Diagnosis and Treatment of Alzhiemer s Disease Roy Yaari, MD, MAS Director, Memory Disorders Clinic, Banner Alzheimer s Institute 602-839-6900 Outline Introduction Alzheimer s disease (AD)Guidelines -revised

More information

Fact Sheet Alzheimer s disease

Fact Sheet Alzheimer s disease What is Alzheimer s disease Fact Sheet Alzheimer s disease Alzheimer s disease, AD, is a progressive brain disorder that gradually destroys a person s memory and ability to learn, reason, make judgements,

More information

Dementia and Healthy Ageing : is the pathology any different?

Dementia and Healthy Ageing : is the pathology any different? Dementia and Healthy Ageing : is the pathology any different? Professor David Mann, Professor of Neuropathology, University of Manchester, Hope Hospital, Salford DEMENTIA Loss of connectivity within association

More information

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease

The current state of healthcare for Normal Aging, Mild Cognitive Impairment, & Alzheimer s Disease The current state of healthcare for Normal Aging, g, Mild Cognitive Impairment, & Alzheimer s Disease William Rodman Shankle, MS MD FACP Director, Alzheimer s Program, Hoag Neurosciences Institute Neurologist,

More information

#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by

#CHAIR2015. Miami, Florida. September 24 26, JW Marriott Miami. Sponsored by #CHAIR2015 September 24 26, 2015 JW Marriott Miami Miami, Florida Sponsored by Case Challenge Workshop Alzheimer s Disease Anand Kumar, MD University of Illinois at Chicago, College of Medicine Chicago,

More information

How can the new diagnostic criteria improve patient selection for DM therapy trials

How can the new diagnostic criteria improve patient selection for DM therapy trials How can the new diagnostic criteria improve patient selection for DM therapy trials Amsterdam, August 2015 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM)

More information

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE?

HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? EAMA CORE CURRICULUM HOW TO PREVENT COGNITIVE DECLINE.AT MCI STAGE? Sofia Duque Orthogeriatric Unit São Francisco Xavier Hospital Occidental Lisbon Hospital Center University Geriatric Unit, Faculty of

More information

Mild Cognitive Impairment

Mild Cognitive Impairment Mild Cognitive Impairment Victor W. Henderson, MD, MS Departments of Health Research & Policy (Epidemiology) and of Neurology & Neurological Sciences Stanford University Director, Stanford Alzheimer s

More information

AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE

AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE AT RISK, SCI, EMCI: THE ALPHABET SOUP OF PRECLINICAL AND PRODROMAL ALZHEIMER DISEASE Mary Ellen Quiceno, MD, FAAN Associate Professor of Neurology Mary Quiceno, MD discloses she has received honoraria

More information

New life Collage of nursing Karachi

New life Collage of nursing Karachi New life Collage of nursing Karachi Presenter: Zafar ali shah Faculty: Raja khatri Subject: Pathophysiology Topic :Alzheimer s Disease Post RN BScN semester 2 nd Objective Define Alzheimer s Describe pathophysiology

More information

Risk Factor Reduction and Dementia Prevalence Deborah E. Barnes, PhD, MPH

Risk Factor Reduction and Dementia Prevalence Deborah E. Barnes, PhD, MPH Risk Factor Reduction and Dementia Prevalence Deborah E. Barnes, PhD, MPH Associate Professor Psychiatry and Epidemiology & Biostatistics University of California, San Francisco San Francisco VA Medical

More information

Silent Cerebral Strokes: Clinical Outcomes and Management

Silent Cerebral Strokes: Clinical Outcomes and Management Silent Cerebral Strokes: Clinical Outcomes and Management Nagaendran Kandiah Senior Consultant Neurologist, National Neuroscience Institute, Singapore Clinician Scientist, National Medical Research Council,

More information

Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment

Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Roche satellite symposium/educational session CTAD Asia - China Conference Transforming AD in China: From Diagnosis to Treatment Sunday 2 September 2018 Location: Shanghai, China NP/AZD/1807/0003 Complex

More information

Overview of neurological changes in Alzheimer s disease. Eric Karran

Overview of neurological changes in Alzheimer s disease. Eric Karran Overview of neurological changes in Alzheimer s disease Eric Karran Alzheimer s disease Alois Alzheimer 1864-1915 Auguste D. 1850-1906 Case presented November 26 th 1906 Guildford Talk.ppt 20 th March,

More information

Alzheimer s Disease without Dementia

Alzheimer s Disease without Dementia Alzheimer s Disease without Dementia Dr Emer MacSweeney CEO & Consultant Neuroradiologist Re:Cognition Health London Osteopathic Society 13 September 2016 Early diagnosis of Alzheimer s Disease How and

More information

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018

Improving diagnosis of Alzheimer s disease and lewy body dementia. Brain TLC October 2018 Improving diagnosis of Alzheimer s disease and lewy body dementia Brain TLC October 2018 Plan for this discussion: Introduction to AD and LBD Why do we need to improve diagnosis? What progress has been

More information

Prevention, health promotion & early intervention in dementia

Prevention, health promotion & early intervention in dementia Prevention, health promotion & early intervention in dementia Alzheimer New Zealand Conference 2014 Steve Iliffe Professor of Primary Care & Older People University College London Rotorua, New Zealand

More information

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients

CSF Aβ1-42 predicts cognitive impairment in de novo PD patients CSF Aβ1-42 predicts cognitive impairment in de novo PD patients Mark Terrelonge MPH *1, Karen Marder MD MPH 1, Daniel Weintraub MD 2, Roy Alcalay MD MS 1 1 Columbia University Department of Neurology 2

More information

New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist

New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist New diagnostic criteria for Alzheimer s disease and mild cognitive impairment for the practical neurologist Andrew E Budson, 1,2 Paul R Solomon 2,3 1 Center for Translational Cognitive Neuroscience, VA

More information

Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues

Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic Guidelines? The Debate Continues Comments to this discussion are invited on the Alzforum Webinar page. Who Should Use the New Diagnostic s? The Debate Continues Ever since new criteria came out for a research diagnosis of prodromal/preclinical

More information

UNIVERSITY OF CALGARY. Predicting Cognitive Decline in Patients with TIA and Minor Stroke. Muhammad Amlish Munir A THESIS

UNIVERSITY OF CALGARY. Predicting Cognitive Decline in Patients with TIA and Minor Stroke. Muhammad Amlish Munir A THESIS UNIVERSITY OF CALGARY Predicting Cognitive Decline in Patients with TIA and Minor Stroke by Muhammad Amlish Munir A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES IN PARTIAL FULFILMENT OF THE REQUIREMENTS

More information

Johnson, V. E., and Stewart, W. (2015) Traumatic brain injury: Age at injury influences dementia risk after TBI. Nature Reviews Neurology, 11(3), pp. 128-130. (doi:10.1038/nrneurol.2014.241) There may

More information

Moving Targets: An Update on Diagnosing Dementia in the Clinic

Moving Targets: An Update on Diagnosing Dementia in the Clinic Moving Targets: An Update on Diagnosing Dementia in the Clinic Eric McDade DO Department of Neurology School of Medicine Alzheimer Disease Research Center Disclosures No relevant financial disclosures

More information

Delirium, Apo-E status, and AD CSF biomarkers

Delirium, Apo-E status, and AD CSF biomarkers Delirium, Apo-E status, and AD CSF biomarkers Zhongcong Xie, M.D., Ph.D. Geriatric Anesthesia Research Unit Department of Anesthesia, Critical Care and Pain Medicine Massachusetts General Hospital Harvard

More information

UNIVERSITY OF WESTERN ONTARIO

UNIVERSITY OF WESTERN ONTARIO UNIVERSITY OF WESTERN ONTARIO Vladimir Hachinski, CM, MD, FRCPC, DSc Department of Clinical Neurological Sciences University of Western Ontario London, Ontario, Canada Vladimir.hachinski@lhsc.on.ca ALZHEIMER

More information

Dementia is not normal aging!

Dementia is not normal aging! The Future of Alzheimer s Disease Treatment Adam L. Boxer, MD, PhD Director, Alzheimer s Disease Clinical Trials Program Memory and Aging Center Assistant Professor of Neurology University of California,

More information

Outline of Lecture 2/13/2018

Outline of Lecture 2/13/2018 Allan I. Pack, M.B.Ch.B., Ph.D., FRCP John Miclot Professor of Medicine Director, Center for sleep and Circadian Neurobiology University of Pennsylvania Perelman School of Medicine Philadelphia, Pennsylvania

More information

Post Stroke Cognitive Decline

Post Stroke Cognitive Decline Post Stroke Cognitive Decline Deborah A. Levine, MD, MPH Departments of Medicine & Neurology University of Michigan deblevin@umich.edu Presenter Disclosure Information Deborah A. Levine, MD, MPH Post Stroke

More information

Therapeutic Benefits of Caregiver Interventions

Therapeutic Benefits of Caregiver Interventions Therapeutic Benefits of Caregiver Interventions Laura N. Gitlin, Ph.D. Professor, Department Community Public Health, School of Nursing Director, Center for Innovative Care in Aging Johns Hopkins University

More information

Vascular and Degenerative Causes of Cognitive Impairment: How are they linked?

Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? MCI Symposium, Public Education Forum Presented by: Rebecca Gottesman, MD PhD January 20, 2019 1 Disclosures I am an Associate

More information

Dementia. Assessing Brain Damage. Mental Status Examination

Dementia. Assessing Brain Damage. Mental Status Examination Dementia Assessing Brain Damage Mental status examination Information about current behavior and thought including orientation to reality, memory, and ability to follow instructions Neuropsychological

More information

Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies

Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies Case Report Taiwanese Journal of Psychiatry (Taipei) Vol. 25 No. 1 2011 45 Probable Early-onset Alzheimer s Disease Diagnosed by Comprehensive Evaluation and Neuroimage Studies Sin-Yi Chen, M.D. 1, Yuan-Han

More information

Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color.

Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Alzheimer's Disease A mind in darkness awaiting the drink of a gentle color. Mary ET Boyle, Ph. D. Department of Cognitive Science UCSD Gabriel García Márquez One Hundred Years of Solitude Alois Alzheimer

More information

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology

Dementia. Stephen S. Flitman, MD Medical Director 21st Century Neurology Dementia Stephen S. Flitman, MD Medical Director 21st Century Neurology www.neurozone.org Dementia is a syndrome Progressive memory loss, plus Progressive loss of one or more cognitive functions: Language

More information

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease

The added value of the IWG-2 diagnostic criteria for Alzheimer s disease The added value of the IWG-2 diagnostic criteria for Alzheimer s disease Miami, January 2016 Bruno Dubois Head of the Dementia Research Center (IMMA) Director of INSERM Research Unit (ICM) Salpêtrière

More information

Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD

Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for Clinical Practice. Hypothesized Key Players in the Pathogenesis of AD AD is a Neurodegenerative Disease as Seen in the PET Scan and is Characterized by Amyloid Plaques and Neurofibrillary Tangles Mild Cognitive Impairment or Mild Neurocognitive Disorder: Implications for

More information

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH

RESEARCH AND PRACTICE IN ALZHEIMER S DISEASE VOL 10 EADC OVERVIEW B. VELLAS & E. REYNISH EADC BRUNO VELLAS 14/01/05 10:14 Page 1 EADC OVERVIEW B. VELLAS & E. REYNISH (Toulouse, France, EU) Bruno Vellas: The European Alzheimer's Disease Consortium is a European funded network of centres of

More information

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by

November 16-18, 2017 Hotel Monteleone New Orleans, LA. Provided by November 16-18, 2017 Hotel Monteleone New Orleans, LA Provided by Treatment Targets in Alzheimer s Disease W. Vaughn McCall, MD, MS Professor and Case Distinguished University Chairman Department of Psychiatry

More information

Outline. Facts and figures Action plans Early / correct diagnosis Conclusions

Outline. Facts and figures Action plans Early / correct diagnosis Conclusions Outline Facts and figures Action plans Early / correct diagnosis Conclusions Dementia: the greatest chalenge. Time to act now Philip Scheltens Professor of Neurology VU University Medical Center Amsterdam

More information

Erin Cullnan Research Assistant, University of Illinois at Chicago

Erin Cullnan Research Assistant, University of Illinois at Chicago Dr. Moises Gaviria Distinguished Professor of Psychiatry, University of Illinois at Chicago Director of Consultation Liaison Service, Advocate Christ Medical Center Director of the Older Adult Program,

More information

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey

ALZHEIMER S DISEASE. Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey ALZHEIMER S DISEASE Mary-Letitia Timiras M.D. Overlook Hospital Summit, New Jersey Topics Covered Demography Clinical manifestations Pathophysiology Diagnosis Treatment Future trends Prevalence and Impact

More information

Memory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging

Memory Matters: Learning Objectives: Synapses, Age, and Health. Neuronal Synapses DISCLOSURE DECLARATION. Cognition and Normal Aging Standard Deviations from Mean Memory Matters: Preventing and Treating Late-Life, Cognitive Decline Daniel L. Murman, MD, MS Director, Behavioral and Geriatric Neurology Program Professor & Vice Chair,

More information

Dementia, Cognitive Aging Services and Support

Dementia, Cognitive Aging Services and Support Dementia, Cognitive Aging Services and Support Ronald C. Petersen, Ph.D., M.D. Professor of Neurology Mayo Clinic College of Medicine Rochester, MN NASUAD Washington September 2, 2015 Disclosures Pfizer,

More information

Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease

Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease Flicker Light-Induced Retinal Vasodilation is Lower in Alzheimer s Disease Mojtaba Golzan (Research Fellow-Alzheimer s Australia) Department of Clinical Medicine, Macquarie University Ms. Dana Georgevsky

More information

Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS)

Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) Alzheimer s Biomarkers Consortium of Down Syndrome (ABC-DS) AN OVERVIEW (with material provided by Ben Handen & Nicole Schupf) https://www.nia.nih.gov/research/abc-ds Alzheimer s Biomarkers Consortium

More information

Theme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods

Theme Topics Subtopics. Basic and Translational Science. Development of New Models and Analysis Methods Basic and Translational Science Development of New Models and Analysis Methods α-synuclein Amyloid/Abeta Behavioral models Inflammation Novel assays and technologies Screening studies/platforms Seeding

More information

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre

Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Yin-Hui Siow MD, FRCPC Director of Nuclear Medicine Southlake Regional Health Centre Today Introduction to CT Introduction to MRI Introduction to nuclear medicine Imaging the dementias The Brain ~ 1.5

More information

KA Toulis, K. Dovas, M. Tsolaki. The endocrine facets of Alzheimer s disease and dementia-related disorders

KA Toulis, K. Dovas, M. Tsolaki. The endocrine facets of Alzheimer s disease and dementia-related disorders KA Toulis, K. Dovas, M. Tsolaki The endocrine facets of Alzheimer s disease and dementia-related disorders Sex hormones Calcium metabolism GH/IGF-I Thyroid axis Metabolic hormones + dementia Sex hormones

More information

Objective 4/22/2019. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation.

Objective 4/22/2019. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation. Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory

More information

Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation

Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Interaction of Cardiovascular Disease and Alzheimer s Disease: Implications for Cardiopulmonary Rehabilitation Dereck Salisbury, PhD Assistant Professor, Clinical Exercise Physiologist Director: Laboratory

More information

The Aging Brain The Aging Brain

The Aging Brain The Aging Brain The Aging Brain The Aging Brain R. Scott Turner, MD, PhD Director, Memory Disorders Program Professor, Department of Neurology Georgetown University Washington, DC memory.georgetown.edu rst36@georgetown.edu

More information

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation

Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation Round table: Moderator; Fereshteh Sedaghat, MD, PhD Brain Mapping in Dementias and Non-invasive Neurostimulation 1. Reflection of Mild Cognitive Impairment (MCI) and Dementias by Molecular Imaging, PET

More information

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

PDF hosted at the Radboud Repository of the Radboud University Nijmegen PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a postprint version which may differ from the publisher's version. For additional information about this

More information

Mary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013

Mary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013 Preventing and Treating Alzheimer's Disease: Recruiting Patients for Clinical Trials Mary Sano, PhD Mount Sinai School of Medicine James J Peters Veterans Affairs Hospital June 15, 2013 Goals and Learning

More information

Diabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian

Diabetes Mellitus and Dementia. Andrea Shelton & Adena Zadourian Diabetes Mellitus and Dementia Andrea Shelton & Adena Zadourian Abstract Diabetes mellitus increases the risk for developing dementia...but there is inconsistency with the subtypes of dementia Diabetes

More information

Mild Cognitive Impairment Symposium January 19 and 20, 2013

Mild Cognitive Impairment Symposium January 19 and 20, 2013 Highlights of Biomarker and Clinical Outcomes in Recent AD Treatment Trials Stephen Salloway, MD, MS Professor of Neurology and Psychiatry Alpert Medical School, Brown University Mild Cognitive Impairment

More information

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia

Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia 86 Neuropsychiatric Manifestations in Vascular Cognitive Impairment Patients with and without Dementia Pai-Yi Chiu 1,3, Chung-Hsiang Liu 2, and Chon-Haw Tsai 2 Abstract- Background: Neuropsychiatric profile

More information

Synaptic changes in dementia: links to cognition and behaviour

Synaptic changes in dementia: links to cognition and behaviour Synaptic changes in dementia: links to cognition and behaviour Paul T Francis, PhD Professor of Neurochemistry Director, Brains for Dementia Research Agenda Discuss synaptic changes in various dementias

More information

The ABCs of Dementia Diagnosis

The ABCs of Dementia Diagnosis The ABCs of Dementia Diagnosis Dr. Robin Heinrichs, Ph.D., ABPP Board Certified Clinical Neuropsychologist Associate Professor, Psychiatry & Behavioral Sciences Director of Neuropsychology Training What

More information

ALZHEIMER S DISEASE FACTOIDS & STATISTICS

ALZHEIMER S DISEASE FACTOIDS & STATISTICS ALZHEIMER S DISEASE FACTOIDS & STATISTICS ~ 4 million affected in US alone 6-8% if 65+ years old, 30-50% if 80+ By 2030, in US >65 million people >65+ (---> ~14 million with AD) AD is one of the top 10

More information

BGS Spring Risk Factors and Preventative Strategies for Dementia

BGS Spring Risk Factors and Preventative Strategies for Dementia Risk Factors and Preventative Strategies for Dementia Dr Blossom Stephan Senior Lecturer (in Risk Prediction) Newcastle University Institute for Ageing and Institute of Health and Society BGS Spring Meeting

More information

Regulatory Challenges across Dementia Subtypes European View

Regulatory Challenges across Dementia Subtypes European View Regulatory Challenges across Dementia Subtypes European View Population definition including Early disease at risk Endpoints in POC studies Endpoints in pivotal trials 1 Disclaimer No CoI The opinions

More information

POST STROKE DEMENTIA: DIAGNOSIS & INTERVENTION. Danielle E. Eagan, Ph.D. Barrow Neurological Institute Stroke Symposium October 13, 2018

POST STROKE DEMENTIA: DIAGNOSIS & INTERVENTION. Danielle E. Eagan, Ph.D. Barrow Neurological Institute Stroke Symposium October 13, 2018 POST STROKE DEMENTIA: DIAGNOSIS & INTERVENTION Danielle E. Eagan, Ph.D. Barrow Neurological Institute Stroke Symposium October 13, 2018 Overview Stroke & Cognitive Impairment The VCI continuum & terminology

More information

Dementia and Alzheimer s disease

Dementia and Alzheimer s disease Since 1960 Medicine Korat โรงพยาบาลมหาราชนครราชส มา Dementia and Alzheimer s disease Concise Reviews PAWUT MEKAWICHAI MD DEPARTMENT of MEDICINE MAHARAT NAKHON RATCHASIMA HOSPITAL 1 Prevalence Increase

More information

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease

DEMENTIA? 45 Million. What is. WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: 70% Dementia is not a disease What is PRESENTS DEMENTIA? WHAT IS DEMENTIA Dementia is a disturbance in a group of mental processes including: Memory Reasoning Planning Learning Attention Language Perception Behavior AS OF 2013 There

More information

Evidence-Based Treatments and Community Resources for Persons with Memory Loss. Prevention vs. Treatment

Evidence-Based Treatments and Community Resources for Persons with Memory Loss. Prevention vs. Treatment Evidence-Based Treatments and Community Resources for Persons with Memory Loss Presented by: Sandy C. Burgener, Ph.D., R.N., FAAN Associate Professor Emerita University of Illinois College of Nursing Adjunct

More information

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing

The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing The Australian Imaging Biomarkers and Lifestyle Flagship Study of Ageing. (AUSTRALIAN ADNI) July 2013 UPDATE Imaging Christopher Rowe MD Neuroimaging stream leader June 2013 The Australian Imaging Biomarkers

More information

Assessing and Managing the Patient with Cognitive Decline

Assessing and Managing the Patient with Cognitive Decline Assessing and Managing the Patient with Cognitive Decline Center of Excellence For Alzheimer s Disease for State of NY Capital Region Alzheimer s Center of Albany Medical Center Earl A. Zimmerman, MD Professor

More information

Tammie Benzinger, MD, PhD

Tammie Benzinger, MD, PhD Tammie Benzinger, MD, PhD benzingert@wustl.edu Disclosure: Tammie L.S. Benzinger, M.D., Ph.D. Research Support / Grants: NIH/NIA 5P01AG026276, 1U01AG032438, AG003991-27, 1R01NS066905-01, 1P01NS059560-01A1,

More information

Cognitive Reserve In Alzheimer s Disease: Implications for Detection and Prevention

Cognitive Reserve In Alzheimer s Disease: Implications for Detection and Prevention Cognitive Reserve In Alzheimer s Disease: Implications for Detection and Prevention MATTHEW J. BEELEN, M.D. Program Director, Geriatric Medicine Fellowship Department of Family and Community Medicine Lancaster

More information

CASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories?

CASE 49. What type of memory is available for conscious retrieval? Which part of the brain stores semantic (factual) memories? CASE 49 A 43-year-old woman is brought to her primary care physician by her family because of concerns about her forgetfulness. The patient has a history of Down syndrome but no other medical problems.

More information

Next patient please Dementia Clare Hawley 2018

Next patient please Dementia Clare Hawley 2018 Next patient please Dementia Clare Hawley 2018 I have no conflict of interest to declare Dr Clare Hawley Associate Specialist Cardiology Chesterfield Royal Hospital GPwSI Refractory Angina Hon Clinical

More information

An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease

An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease An integrated natural disease progression model of nine cognitive and biomarker endpoints in patients with Alzheimer s Disease Angelica Quartino 1* Dan Polhamus 2*, James Rogers 2, Jin Jin 1 212, Genentech

More information

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia

What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia What if it s not Alzheimer s? Update on Lewy body dementia and frontotemporal dementia Dementia: broad term for any acquired brain condition impairing mental function such that ADLs are impaired. Includes:

More information

MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH

MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH MEDICAL LIFESTYLE INTERVENTIONS FOR BRAIN HEALTH Nicci Kobritz, President Center for Brain Health & Youthful Aging Home Health 1 Our Goal Reduce the impact of modifiable medical risk factors associated

More information

Form D1: Clinician Diagnosis

Form D1: Clinician Diagnosis Initial Visit Packet Form D: Clinician Diagnosis NACC Uniform Data Set (UDS) ADC name: Subject ID: Form date: / / Visit #: Examiner s initials: INSTRUCTIONS: This form is to be completed by the clinician.

More information

Self-Compassion in Taking & Giving Care. Objectives

Self-Compassion in Taking & Giving Care. Objectives Self-Compassion in Taking & Giving Care Tiffany Chow, MD, MSc, FAAN Senior Scientist, Baycrest Health Sciences Associate Professor, University of Toronto Neurology and Geriatric Psychiatry Objectives Is

More information

Alzheimer s Disease Centers meeting San Diego, CA October 14, NIA-Division of Neurosciences update"

Alzheimer s Disease Centers meeting San Diego, CA October 14, NIA-Division of Neurosciences update Alzheimer s Disease Centers meeting San Diego, CA October 14, 2017 NIA-Division of Neurosciences update" Eliezer Masliah, M.D. Director, Division of Neuroscience, National Institute on Aging, NIH AD grants

More information

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge

Introduction, use of imaging and current guidelines. John O Brien Professor of Old Age Psychiatry University of Cambridge Introduction, use of imaging and current guidelines John O Brien Professor of Old Age Psychiatry University of Cambridge Why do we undertake brain imaging in AD and other dementias? Exclude other causes

More information